The seRNA principle and its in vitro and in vivo proof of concept (POC) studies are now published in Nature Communications!

The seRNA platform technology establishes a new treatment modality via selectively expressed RNAs. The functional mechanism of seRNA, its targeting specificity, and its treatment approach as therapeutic modality against cancer (glioblastoma) and viral diseases has now been published.

The publication demonstrates the in vitro and in vivo POC for glioblastoma, as an example of an oncological indication. Additionally, it illustrates the simple adaptation of the seRNA technology to other therapeutic areas and numerous indications.

For more information and details to our unique, proprietary platform, see also:
https://doi.org/10.1038/s41467-024-55547-6

RNA therapeutics are highly dependent on in vivo transfer systems. For this purpose, we investigated the exclusively in-licensed and further developed proprietary LNP (fLNP) technology. In our latest biodistribution study,  fLNPs have demonstrated their true potential and biocompatibility.

In-house in vivo analyses, as well as extended mouse studies, conducted by our partner CRO, have confirmed the extraordinary transfer efficiency as well as pre-targeting ability to different organs, depending on formulation and functionalization capacity, of fLNPs.

In these biodistribution studies, fLNPs were superior to commercial in vivo delivery reagents when directly compared. The successful conclusion of these studies, further strengthens the broad applicability of seRNA therapeutics in various indications.

We are very proud to announce that we have closed our first financing round and secured further funding for SRTD. The round was led by High-Tech Gründerfonds (HTGF), alongside renowned business angels who have backed the technology from its inception.

We will use the fresh capital to accelerate the development of our proprietary seRNA technology, which aims to develop highly efficient RNA-based drugs that are active only in diseased cells.

With the closing of this financing round, we are able to confirm the robustness of the platform and to attract further partners.

Our aim is to bring drug candidates for liver cancer into clinical development within the next three years and to make the platform available for other applications.

https://www.htgf.de/de/htgf-seed-srtd-biotech/

An seRNA against breast cancer stops tumor growth in a xenograft breast cancer mouse model after three intravenous treatments within one week.

In the MTD study, healthy mice treated with seRNA delivered by fLNPs, showed no toxic side effects at any concentrations tested (up to 2 mg/kg), allowing multiple systemic treatments per week.

While control animals showed exponential tumor growth, seRNA-treated mice showed tumor growth inhibition and a reduction in tumor volume after just three treatments within one week.

Thus, seRNAs are not just highly selective but also highly effective in vivo, illustrating the platform character of this novel, proprietary approach.

We have expanded our IP portfolio for our key technology. 

Whilst our original patent application to deliver seRNA via plasmid DNA is currently in its nationalization phase, with Japan already granting the patent and other countries expecting to do so shortly, we have last week submitted a new patent application to protect the delivery of improved seRNA as an RNA molecule.

Thus, this establishes seRNA as novel platform technology. It enables target cell selective RNA therapeutics in numerous indications and therapeutics areas and by selection of a delivery approach that is best suited for the indication we intend to target.